{"id":"anrotinib","rwe":[],"tags":[],"phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05981157","NCT05089643","NCT06585644","NCT05747521","NCT06429397","NCT05683704","NCT06340165","NCT05608785","NCT06678230"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Anrotinib","companyId":"henan-cancer-hospital","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:07:35.944970+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"companyName":"Henan Cancer Hospital","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Anrotinib","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05981157","phase":"Phase 2","title":"Anrotinib Combined With Tirelizumab in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhongshan People's Hospital, Guangdong, China","isPivotal":false,"enrollment":27,"indication":"Nasopharyngeal Carcinoma","completionDate":"2025-12-30"},{"nctId":"NCT05089643","phase":"Phase 2","title":"Anrotinib in Combination With Capecitabine in the Single-arm, Open Phase II Treatment of Relapsed or Metastatic Triple-negative Breast Cancer Clinical Research","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","isPivotal":false,"enrollment":35,"indication":"Metastatic Triple-Negative Breast Cancer","completionDate":"2022-12-31"},{"nctId":"NCT06585644","phase":"Phase 2","title":"Furmonertinib in Combination with Anlotinib and Chemotherapy As Neoadjuvant Treatment for Resectable, Stage II-III EGFR-Mutated Non-Small Cell Lung Cancer: a Single-Arm, Open-Label, Phase II Clinical ","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","isPivotal":false,"enrollment":44,"indication":"Lung Cancer (NSCLC)","completionDate":"2030-06-01"},{"nctId":"NCT05747521","phase":"NA","title":"A Single Arm, Single Center, Prospective Clinical Study of Anrotinib Hydrochloride Combined With Doxorubicin in the Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","isPivotal":false,"enrollment":85,"indication":"Soft Tissue Sarcoma","completionDate":"2024-09-30"},{"nctId":"NCT06429397","phase":"Phase 2","title":"A Single-arm, Multicenter, Prospective Phase II Clinical Study of Anlotinib Combined With Benmelstobart in the First-line Treatment of Advanced Pheochromocytoma/Paraganglioma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","isPivotal":false,"enrollment":22,"indication":"Pheochromocytoma","completionDate":"2027-05-28"},{"nctId":"NCT05683704","phase":"Phase 2","title":"Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Medical University Cancer Institute and Hospital","isPivotal":false,"enrollment":30,"indication":"Recurrent/Refractory Classical Hodgkin's Lymphoma","completionDate":"2026-05-31"},{"nctId":"NCT06340165","phase":"N/A","title":"A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","isPivotal":false,"enrollment":153,"indication":"Breast Cancer","completionDate":"2025-06"},{"nctId":"NCT05608785","phase":"Phase 1","title":"Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","isPivotal":false,"enrollment":45,"indication":"Gastric Cancer, Gastroesophageal-junction Cancer","completionDate":"2024-10-01"},{"nctId":"NCT06678230","phase":"Phase 2","title":"Multicenter, Single-Arm, Phase II Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer.","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","isPivotal":false,"enrollment":40,"indication":"Breast Cancer","completionDate":"2025-10-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:07:35.944970+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}